Replies to post #386472 on Anavex Life Sciences Corp (AVXL)

[frrol]

It's an excellent article. There is a metric ton of investor attention on AD this week with CTAD and the additional Lecanemab data (which now includes some sub-grouping). Anavex has an opportunity to make a splash tomorrow. Fingers crossed. This SA article by Ingham is right on (though I'm far more bullish than he is on potential for positive AD results; I think worst case is high dose sub-grouping).

[Doktornolittle]

"Very balanced..." Balanced my ass. 100 Transparent that this Edmund Ingham is a phony dude. In the one page article (legitimate Seeking Alpha articles are almost always much longer than that) he says "The decline in AVXL stock price after a fiscal Q422 earnings call in which management declined to discuss the data does not inspire confidence that results will be positive.". Edmund, Edmund Edmund.
They have already PR'd that they are announcing top line in an Oral Presentation at CTAD on Dec 1. Why would they announce that, and then go against that public statement and announce top line a few days early at the QReport? No company would do that. In fact most conference rules restrict the authors from revealing data early. This conference is probably the same. And the crooks that hired Edmund know that too. Pure stock manipulation. Illegal as hell. I think your a crook Edmund. (Edmund is not a poster on ihub and therefore not subject to it's protections regarding being polite, nor deserving thereof).